Tag: Eiger BioPharmaceuticals
“Without drug trials, we can’t move forward”: One patient’s hope to participate in the ubenimex trials
Barbara desires to help fellow lymphedema patients by participating in the ULTRA study.
A conversation with Dr. Joanne Quan, Chief Medical Officer at Eiger BioPharmaceuticals, about the ubenimex trial, the Stanford studies, and the important role patients play in the development of new therapies.
This summer has been a big one for lymphedema and lymphatic research news! Back in June we talked about the Stanford BioBridge study, where researchers found that surgically implanted nanofibers stimulated growth of new lymph vessels, bypassing lymph blockages and reducing swelling in affected limbs. Now there’s a new study that has the potential to be just as much…